Eli Lilly Operating Income 2010-2022 | LLY

Eli Lilly annual/quarterly operating income history and growth rate from 2010 to 2022. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
  • Eli Lilly operating income for the quarter ending March 31, 2022 was $2.404B, a 108.11% increase year-over-year.
  • Eli Lilly operating income for the twelve months ending March 31, 2022 was $7.606B, a 35.28% increase year-over-year.
  • Eli Lilly annual operating income for 2021 was $6.357B, a 4.94% increase from 2020.
  • Eli Lilly annual operating income for 2020 was $6.058B, a 21.79% increase from 2019.
  • Eli Lilly annual operating income for 2019 was $4.974B, a 40.74% increase from 2018.
Eli Lilly Annual Operating Income
(Millions of US $)
2021 $6,357
2020 $6,058
2019 $4,974
2018 $3,535
2017 $2,003
2016 $3,261
2015 $2,689
2014 $2,660
2013 $5,370
2012 $4,734
2011 $5,529
2010 $6,530
2009 $5,587
Eli Lilly Quarterly Operating Income
(Millions of US $)
2022-03-31 $2,404
2021-12-31 $1,917
2021-09-30 $1,881
2021-06-30 $1,403
2021-03-31 $1,155
2020-12-31 $1,992
2020-09-30 $1,278
2020-06-30 $1,197
2020-03-31 $1,591
2019-12-31 $1,400
2019-09-30 $1,431
2019-06-30 $1,498
2019-03-31 $645
2018-12-31 $900
2018-09-30 $1,343
2018-06-30 $-5
2018-03-31 $1,296
2017-12-31 $279
2017-09-30 $542
2017-06-30 $1,200
2017-03-31 $-17
2016-12-31 $679
2016-09-30 $944
2016-06-30 $923
2016-03-31 $716
2015-12-31 $328
2015-09-30 $961
2015-06-30 $875
2015-03-31 $525
2014-12-31 $309
2014-09-30 $598
2014-06-30 $887
2014-03-31 $866
2013-12-31 $879
2013-09-30 $1,545
2013-06-30 $1,503
2013-03-31 $1,444
2012-12-31 $1,011
2012-09-30 $1,140
2012-06-30 $1,202
2012-03-31 $1,381
2011-12-31 $992
2011-09-30 $1,586
2011-06-30 $1,589
2011-03-31 $1,361
2010-12-31 $1,336
2010-09-30 $1,753
2010-06-30 $1,782
2010-03-31 $1,660
2009-12-31 $550
2009-09-30 $1,686
2009-06-30 $1,597
2009-03-31 $1,754
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $297.134B $28.318B
Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $472.758B 18.18
Pfizer (PFE) United States $281.050B 9.80
AbbVie (ABBV) United States $264.095B 11.58
Merck (MRK) United States $232.650B 13.14
Novartis AG (NVS) Switzerland $181.123B 13.18
GlaxoSmithKline (GSK) United Kingdom $108.662B 12.69
Novo Nordisk (NVO) Denmark $0.000B 32.27